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vated form of the transcription factor signal transducer and 
activator of transcription protein 3 proved the biological ac-
tivity of the bacteria-produced human IL-10. 
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 Introduction 
 Gram-negative bacteria use different types of secre-
tion systems for the transport of proteins to the periplas-
mic space [Pugsley, 1993]. Secretory proteins are usually 
synthesized as precursors with an N-terminal signal se-
quence which enables export out of the cytoplasma [de 
Keyzer et al., 2003]. Secretory production of heterologous 
proteins in  Escherichia  coli displays several advantages 
compared to cytoplasmic production, such as the avoid-
ance of inclusion body formation, correct disulfide bridg-
ing and an authentic N-terminal amino acid sequence 
after signal peptide cleavage without methionine exten-
sion [Choi and Lee, 2004].
 Human interleukin-10 (hIL-10) plays a major role in 
the regulation of inflammation and exerts its immuno-
suppressive properties mainly via its effect on dendritic 
cells and macrophages resulting in inhibition of antigen 
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 Abstract 
 Interleukin-10 (IL-10) is a potent anti-inflammatory cytokine, 
with therapeutic applications in inflammatory bowel dis-
ease. For the in situ delivery of IL-10 by  Escherichia coli as car-
rier chassis, a modified transporter was designed with the 
ability to secrete biologically active IL-10. De novo DNA syn-
thesis comprised a 561-bp fragment encoding the signal se-
quence of the  E. coli outer membrane protein F fused in 
frame to an  E. coli codon-optimized mature human IL-10 
gene under control of a T7 promoter. The construct was 
overexpressed in  E. coli laboratory strains,  E. coli BL21 (DE3) 
and  E. coli MDS42:T7. The mean concentrations of human IL-
10 in the periplasm and culture supernatant of  E. coli BL21 
(DE3) were 355.8  8 86.3 and 5.7  8 1.7 ng/ml, respectively. 
The molecular mass of the recombinant  E. coli -derived hu-
man IL-10 was 19 kDa, while under non-reducing conditions 
the native IL-10 dimer could be demonstrated. Reduction of 
tumor necrosis factor-  secretion in lipopolysaccharide-
stimulated mouse macrophages and detection of the acti-
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presentation, inhibition of dendritic cell differentiation 
and maturation, and inhibition of release of proinflam-
matory cytokines such as tumor necrosis factor-  (TNF-
  ) [Mosser and Zhang, 2008]. In experimental settings, 
mice genetically deficient in IL-10 have shown to suc-
cumb to severe colitis [Kühn et al., 1993], whereas sys-
temic application of recombinant IL-10 could prevent the 
development of the disease [Herfarth et al., 1996]. A pilot 
study conducted on healthy human volunteers demon-
strated suppression of proinflammatory cytokine pro-
duction such as IL-1 and TNF-  upon IL-10 administra-
tion [Chernoff et al., 1995]. Based on these observations, 
hIL-10 has emerged as a promising option for the treat-
ment of various autoimmune disorders including in-
flammatory bowel diseases [Mosser and Zhang, 2008]. 
However, administration of IL-10 by oral intake or injec-
tion of either recombinant protein or gene therapeutic 
vectors is limited by the acid sensitivity of the protein 
[Masood et al., 1995] and the induction of side effects [Fe-
dorak et al., 2000; Schreiber et al., 2000; Tilg et al., 2002]. 
Therefore, an efficient delivery system specifically target-
ing the colon is highly desirable. Colonic IL-10 produc-
tion by rectal injection of adenoviral vectors expressing 
IL-10 has been demonstrated [Lindsay et al., 2003], but 
may suffer from inconvenient delivery of the vector. Al-
ternatively, genetically modified microorganisms pro-
vide a possible means for the in situ delivery of therapeu-
tic proteins [Beninati et al., 2000; Krüger et al., 2002; 
Steidler et al., 1998].  Lactococcus lactis and  Shigella flexne-
ri strains have been engineered to secrete biologically ac-
tive IL-10 [Chamekh et al., 2008; Steidler et al., 2000]. 
However, the good colonization properties and the lack 
of virulence determinants may render nonpathogenic  E. 
coli strains such as probiotic  E. coli Nissle 1917 a more 
ideal carrier chassis for intestinal drug delivery.
 In this study, we constructed a modified bacterial 
transporter which enables T7 promoter-dependent ex-
pression and secretion of biologically active hIL-10 in lab-
oratory  E. coli  strains using an  E. coli codon-optimized 
synthetic hIL-10 gene preceded by the leader sequence of 
the outer membrane protein F (OmpF), a pore-forming 
protein of  E. coli .
 Results and Discussion 
 Design and Cloning of the Artificial hIL-10 
Transporter 
 An  E. coli codon-optimized nucleotide sequence was 
generated from the hIL-10 gene sequence (537 bp; Gen-
Bank accession No. NM_000572). The 54-bp N-terminal 
eukaryotic signal sequence was replaced by the first 66 
nucleotides of the  ompF gene of  E. coli K-12 MG1655 
(GenBank accession No. NC_000913.2) coding for the
22 aa OmpF signal peptide. Using SignalP 3.0 soft-
ware (http://www.cbs.dtu.dk/services/SignalP/, Techni-
cal University of Denmark), a high cleavage probability 
(score of 1.0) was predicted between aa position 22 and 23 
(ANA 22 – S 23 P), delivering the mature form of the hIL-10 
protein with authentic N-terminus. Thus, a 561-bp DNA 
fragment was de novo synthesized in which the signal 
sequence of the  E. coli ompF gene was fused in frame to 
the 5  end of the mature hIL-10 synthetic gene. The DNA 
fragment was subsequently cloned into the BAC vector 
pSG1107 under the control of the T7 promoter, giving 
plasmid pSG1502 ( fig. 1 ). Due to low protein expression 
in pSG1502-transformed  E. coli BL21 (DE3) cells (data 
not shown), a 683-bp PCR fragment of pSG1502 includ-
ing the promoter region and  ompF - hIL-10 construct was 
subcloned into pUC19 ( fig. 1 ). The new expression vector, 
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pAZ1, was isolated, sequenced, and used to transform  E. 
coli BL21 (DE3) and MDS42:T7 cells.
 Validation of hIL-10 Expression 
 In vitro production and secretion of recombinant hIL-
10 by the modified transporter construct was demon-
strated in  E. coli BL21 (DE3) and MDS42:T7 cells using a 
commercial sandwich ELISA. Overnight cultures were 
pelleted to collect the supernatant and were treated with 
osmotic shock to separate the periplasmic and cytoplas-
mic fraction. The mean hIL-10 concentrations of the cul-
ture supernatant and periplasmic fraction of  E. coli BL21 
(DE3) were 5.8  8 1.7 and 355.8  8 86.3 ng/ml, respec-
tively. As negative control, supernatant and periplasmic 
fraction from pUC19-transformed  E. coli BL21 (DE3) 
cells were used, and the measured OD values were below 
the cutoff of the assay (data not shown). Expression of re-
combinant hIL-10 was significantly reduced in  E. coli 
MDS42:T7 cells with hIL-10 levels being approximately 
tenfold lower than in  E. coli BL21 (DE3) cells (data not 
shown). A number of signal sequences have been em-
ployed for efficient secretory production of heterologous 
proteins in  E. coli via the Sec-dependent secretion path-
way, including pectate lyase B (PelB), outer membrane 
protein A (OmpA), alkaline phosphatase (PhoA), endox-
ylanase, and heat-stable enterotoxin 2 (StII) [Choi and 
Lee, 2004]. The N-terminal portion of OmpF, a major 
outer membrane porin of  E. coli , has also been success-
fully applied for secretion of foreign gene products in  E. 
coli [Nagahari et al., 1985; Rockenbach et al., 1991]. By 
fusing the OmpF signal sequence encompassing the first 
22 aa of the OmpF protein to the mature hIL-10 protein, 
an artificial transporter was created which allowed trans-
location of recombinant hIL-10 across the cytoplasmic 
membrane, thus showing that the modified transporter 
was compatible with the host secretion apparatus. The 
efficiency of the export was further substantiated by the 
fact that no recombinant hIL-10 protein could be detect-
ed in the cytoplasmic cell fraction by both ELISA and 
immunoblot analysis (data not shown). Interestingly, the 
recombinant hIL-10 protein also appeared in the culture 
medium in significant concentrations. Given the high 
hIL-10 concentration gradient across the outer cell mem-
brane, the secretion of the recombinant protein into the 
culture medium was not quantitative. Whether secretion 
of hIL-10 into the culture medium was selective is un-
known since the amount of representative periplasmic 
proteins such as   -lactamase or alkaline phosphatase was 
not assessed. The outer membrane of  E. coli contains pro-
teins such as OmpF, OmpC and others which serve as 
passive diffusion pores for small hydrophilic molecules 
[Nikaido and Vaara, 1985]. However, the pores are likely 
too small for the hIL-10 molecules to be released (mo-
lecular weight of the monomer and dimer is 18.6 and 37.2 
kDa, respectively) since the pores’ exclusion limit is a mo-
lecular weight of approximately 700 Da [Nagahari et al., 
1985]. Furthermore, the physicochemical properties of 
hIL-10 with many exposed hydrophobic residues would 
poorly match the pores’ hydrophilic character [Zdanov et 
al., 1995]. Therefore, hIL-10 found in the culture medium 
most probably resulted from leakage from lysed bacterial 
cells.
 Processing of Signal Peptide Sequence 
 One advantage of secretory protein production in  E. 
coli is that, if the gene of interest is correctly fused to the 
cleavage site, the authentic N-terminus without Met ex-
tension can be realized after cleavage by the signal pepti-
dase. The C-domain of the OmpF signal peptide con-
forms to the (–3, –1) rule [von Heijne, 1983], with the 
small neutral Ala residue at position –1 and –3 within the 
cleavage site. By replacing the hIL-10 signal sequence 
with the OmpF leader peptide, the original OmpF cleav-
age site sequence changed from ANA^AE to ANA^SP
(^  indicating the beginning of the mature protein). Using 
the SignalP 3.0 algorithm, the cleavage site probability 
was predicted not to be altered significantly by modifica-
tion of the processing site. Thus, processing of the OmpF 
leader peptide should result in the delivery of a recombi-
nant hIL-10 protein with authentic N-terminus. Immu-
noblots were carried out to determine the size of recom-
binant hIL-10 secreted into the periplasm compared to a 
purified mature form of the hIL-10 protein from a bacu-
lovirus expression system (R&D Systems, Minneapolis, 
Minn., USA) as size marker.  Figure 2 a shows an immu-
noblot of the periplasmic fraction of both  E. coli BL21 
(DE3) and MDS42:T7 cells harboring the expression vec-
tor pAZ1. In the periplasm, a hIL-10 product correspond-
ing to the size of the commercial hIL-10 protein can be 
observed. However, due to the low molecular mass of the 
OmpF signal sequence and the poor resolution of an im-
munoblot gel, it cannot be precisely indicated whether or 
not the product of the hIL-10 fusion to the OmpF signal 
sequence is processed correctly during secretion in dif-
ferent  E. coli strains. The absence of unprocessed mate-
rial in the cytoplasm (data not shown) suggests that the 
fusion of hIL-10 to the OmpF signal, a product foreign to 
the  E. coli cell, is fully compatible with the host secretion 
mechanism to allow complete secretion.
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 E. coli -Derived hIL-10 Is Dimeric
 The biological activity of hIL-10 strictly depends on its 
dimeric state [Zdanov et al., 1995]. In order to determine 
whether or not the  E. coli -derived recombinant hIL-10 
was properly assembled into dimers, the periplasmic 
fraction of  E. coli BL21 (DE3) containing pAZ1 was con-
centrated and fractionated by blue native polyacrylamide 
gel electrophoresis (BN-PAGE) under non-reducing con-
ditions. Immunoblot analysis confirmed that the recom-
binant hIL-10 was able to form dimers in the oxidative 
milieu of the  E. coli periplasm ( fig. 2 b). Moreover, it ap-
pears that the dimerization of the  E. coli -derived hIL-10 
protein was more efficient than that of its commercially 
produced counterpart. The commercial hIL-10 standard 
which was expressed in a baculovirus infected  Spodop-
tera frugiperda 21 cell line migrated as a smear in the BN-
PAGE at a molecular size range between approximately 
20 and 66 kDa ( fig. 2 b), indicating that the protein was at 
least partly existent in its monomeric form. Since the 
higher dimer/monomer ratio of the  E. coli -derived hIL-10 
was consistent regardless of the amount of protein loaded 
onto the gel, the possibility of an artifact caused by high 
protein concentration can be ruled out. The upper size 
limit of the hIL-10 standard’s immunoblot band was at 
approximately 66 kDa, which might result from mono-
mer aggregation due to protein-protein interaction. How-
ever, different amounts of the hIL-10 standard loaded 
onto the gel, the usage of carrier-free hIL-10 protein with-
out BSA as stabilizer, and preincubation of the hIL-10 
standard with the periplasmic fraction of pUC19-trans-
formed  E. coli BL21 (DE3) cells to rule out any influence 
of periplasmic proteins on the aggregation state of hIL-10 
did not change the migration pattern in the BN-PAGE 
(data not shown). Posttranslational modification such as 
the linkage of carbohydrates to a potential glycosylation 
site at Asn residue 116 [Vieira et al., 1991] due to usage of 
a eukaryotic expression system might also explain the 
difference in the electrophoretic properties of the com-
mercial hIL-10 standard compared to the  E. coli -derived 
protein.
 Biological Activity of  E. coli -Derived hIL-10 
 The ability of the  E. coli -derived hIL-10 to form dimers 
indicated that the recombinant protein was likely to re-
tain its biological activity. We tested this hypothesis by 
assaying the effect of  E. coli -derived recombinant hIL-10 
on downstream components of the IL-10 signaling path-
way [Moore et al., 2001] as well as by testing its inhibitory 
activity on the lipopolysaccharide (LPS)-induced pro-
duction of TNF-  . All anti-inflammatory effects exerted 
by hIL-10 require the activation of signal transducer and 
activator of transcription 3 (STAT3), which acts down-
stream of the hIL-10 receptor in human and murine cel-
lular models [Moore et al., 2001]. We therefore studied the 
ability of  E. coli -derived hIL-10 to phosphorylate the 
Co
m
m
er
ci
al
 h
IL
-1
0
E.
 c
ol
i B
L2
1 
(D
E3
)
E.
 c
ol
i M
D
S4
2:
T7
37
.5
 n
g
75
 n
g
12
0 
n
g
p
U
C
19
 P
P
p
A
Z
1 
PP
p
U
C
19
 P
P
p
A
Z
1 
PP
26
kDa
19
Commercial hIL-10 pAZ1 PP
14
0 
ng
21
0 
ng
26
5 
ng
10
0 
ng
20
0 
ng
27
0 
ng
pU
C1
9 
PP
kDa
67
45
21
 Fig. 2.  a Production and secretion of recombinant hIL-10. hIL-10 
(15 ng/lane) from the periplasmic fraction of pAZ1-transformed 
 E. coli BL21 (DE3) and MDS42:T7 cells was analyzed by immu-
noblotting after separation by reducing SDS-PAGE. Commercial 
recombinant hIL-10 and the periplasmic fraction of pUC19-
transformed  E. coli BL21 (DE3) and MDS42:T7 cells were used as 
controls. One experiment representative of two is shown. PP = 
Periplasmic fraction.  b Assessment of hIL-10 dimerization. Re-
combinant hIL-10 from the periplasmic fraction of pAZ1-trans-
formed  E. coli BL21 (DE3) cells was analyzed by immunoblotting 
after separation by non-reducing BN-PAGE. Commercial recom-
binant hIL-10 produced in a  S. frugiperda 21 ( Sf 21) baculovirus-
derived system and the periplasmic fraction of pUC19-trans-
formed  E. coli BL21 (DE3) cells were used as controls. Different 
amounts of bacteria-derived and commercial hIL-10 were loaded, 
as indicated on top of each lane. One experiment representative 
of two is shown. PP = Periplasmic fraction. 
 a 
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Tyr 705 residue of STAT3. Stimulation of the mouse mac-
rophage cell line J774.1 with the periplasmic fraction of 
pAZ1-transformed  E. coli BL21 (DE3) cells containing 
hIL-10 in a concentration of 100 ng/ml triggered STAT3 
tyrosine phosphorylation within 30 min of incubation 
time ( fig. 3 ). At this concentration, recombinant hIL-10 
was able to elicit STAT3 tyrosine phosphorylation to a 
degree comparable to that observed in response to com-
mercial hIL-10 ( fig. 3 ). No inhibitory effect due to bacte-
rial proteins present in the periplasm was observed since 
STAT3 activation was equally induced by commercial 
hIL-10 spiked with the periplasmic fraction of  E. coli 
BL21 (DE3) cells ( fig. 3 ). STAT3 phosphorylation resulted 
specifically from the presence of recombinant hIL-10, 
since periplasmic fraction of pUC19-transformed  E. coli 
BL21 (DE3) cells lacking the ability of hIL-10 expression 
had no detectable effect on STAT3 activation ( fig.  3 ). 
These results indicate that the  E. coli -derived recombi-
nant hIL-10 protein properly interacted with its receptor 
and initiated the signal transduction cascade.
 One of the key functions of hIL-10 is its ability to 
downregulate proinflammatory cytokine and chemo-
kine expression [Ho and Moore, 1994]. Interaction of 
bacteria with adherent macrophages triggers the release 
of high amounts of the proinflammatory cytokine TNF-
  [D’Hauteville et al., 2002]. We applied this read-out 
system to confirm the functionality of recombinant hIL-
10 produced by bacteria. Stimulation of the mouse mac-
rophage cell line J774.1 was carried out with sterile-fil-
tered periplasm of pUC19-transformed  E. coli BL21 
(DE3) cells. The LPS content of the periplasmic fraction 
of pUC19-transformed  E. coli BL21 (DE3) cells grown 
overnight to similar A 600 values proved to be stable 
enough for the induction of consistent TNF-  levels in 
the culture supernatant of J774.1 cells (data not shown). 
Our experiments demonstrated that  E. coli -derived 
hIL10 was able to suppress the LPS-induced production 
of TNF-  as efficiently as its commercial counterpart 
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( fig. 4 ). The mean reduction of TNF-  levels was 56% for 
incubation of macrophages with recombinant hIL-10 
containing pAZ1 periplasm compared to 57% for treat-
ment with commercial hIL-10 ( fig.  4 ). To determine 
whether the reduction of TNF-  production was a spe-
cific effect dependent on a functional hIL-10 protein, we 
performed the assay both in the presence of neutralizing 
anti-hIL-10 monoclonal antibodies and after heat inac-
tivation of the pAZ1 periplasmic fraction. Neutralization 
of  E. coli -derived hIL-10 by the addition of anti-hIL-10 
antibodies to pAZ1 periplasm and commercial hIL-10 
(data not shown) resulted in TNF-  levels which were 
comparable to those reached after macrophage induc-
tion with pUC19 periplasm ( fig. 4 ), indicating that TNF-
  suppression was hIL-10-dependent. Heat denaturation 
of pAZ1 periplasmic proteins also caused a significant 
increase of TNF-  in the culture supernatant. However, 
TNF-  levels only reached 60% of those generated by 
pUC19 periplasm stimulation of macrophages ( fig.  4 ). 
The lower TNF-  secretion of macrophages following 
incubation with heat-treated bacterial periplasm may be 
due to heat sensitivity of LPS cytokine-inducing activity 
observed at low LPS concentrations [Gao et al., 2006], 
which may also prevail in the periplasm. These results 
indicate that the  E. coli secreted recombinant hIL-10 is 
biologically active, and that  E. coli carrying the secretion 
vector pAZ1 might potentially be used as carriers for in 
situ delivery of therapeutics suitable to downregulate 
production of proinflammatory cytokines in chronic in-
flammatory processes such as inflammatory bowel dis-
ease. For in vivo applications in humans, it is crucial that 
the cytokine can be released from the periplasm in a bio-
logically active form and that a biological containment 
system is provided for the genetically modified organ-
ism. Curtiss and colleagues [Kong et al., 2008] have de-
veloped a recombinant attenuated  Salmonella vaccine in 
which regulated programmed cell lysis enables release of 
protective pneumococcal antigens and confers biological 
containment of recombinant  Salmonella . In the recom-
binant  Salmonella strain, heterologous protein expres-
sion as well as bacterial cell lysis caused by lack of essen-
tial cell wall biosynthesis enzymes are dependent on a 
tightly regulated arabinose operon. This system seems 
well suited for our construct since it also uses a Sec-de-
pendent pathway for antigen transport into the periplas-
mic fraction. Periplasmic enrichment of  E. coli -derived 
recombinant hIL-10 seems to be pivotal in terms of re-
covery of biological activity since recombinant hIL-10 
from culture supernatant of pAZ1-transformed  E. coli 
BL21 (DE3) never showed any biological activity (data 
not shown). Currently, we are adapting this construct to 
the needs of  E. coli in order to combine secretory expres-
sion of heterologous proteins with biological contain-
ment of genetically modified host organisms.
 Experimental Procedures 
 Materials 
 Restriction enzymes, proof-reading Phusion DNA poly-
merase and T4 DNA ligase were purchased from New England 
Biolabs (Beverly, Mass., USA) and were used according to the 
manufacturer’s instructions. GoTaq DNA polymerase was from 
Promega (Madison, Wisc, USA). DNA sequencing kits (ABI 
PRISM BigDye Terminator v3.1 Cycle Sequencing Kit) were ob-
tained from Applied Biosystems (Darmstadt, Germany). Oligo-
nucleotide primers were synthesized by biomers.net (Ulm, Ger-
many). Kits for plasmid mini-prep, DNA gel extraction, and PCR 
purification as well as DyeEx 2.0 Spin Kits for clean-up of se-
quencing reactions were all purchased from Qiagen (Hilden, 
Germany). Molecular mass markers for SDS-PAGE electropho-
resis and nitrocellulose membranes for protein blotting were ob-
tained from Invitrogen (Carlsbad, Calif., USA), native markers 
for BN-PAGE electrophoresis and polyvinylidene difluoride 
(PVDF) membranes (Immo bilon-P) were from SERVA Electro-
phoresis (Heidelberg, Germany). A detection kit for enhanced 
chemiluminescence (ECL SuperSignal West Pico/Femto Sub-
strate) was procured by Thermo Scientific (Rockford, Ill., USA). 
Vivaspin 20 concentrators (10,000 MWCO PES) for enrichment 
of recombinant hIL-10 in different cell fractions were purchased 
from Sartorius (Göttingen, Germany). Culture medium compo-
nents were supplied from BD (Franklin Lakes, N.J., USA). The 
mouse macrophage cell line J774.1 was grown in complete Is-
cove’s medium (Biochrom, Berlin, Germany) supplemented with 
10% FCS at 37   °   C in 5% CO 2 /95% air. Other chemicals obtained 
from commercial sources were all of analytical grade and were 
used without further purification.
 Bacterial Strains, Plasmids and Growth Conditions 
 As cloning host strain,  E. coli MDS 42 [Posfai et al., 2006] was 
used. Protein expression analysis was carried out in  E. coli BL21 
(DE3) [F –  ompT hsdS B (r b – m B – )  gal  dcm (  DE3)] obtained from 
New England Biolabs and  E. coli MDS42:T7. The plasmids used 
in this study were pUC19 (New England Biolabs) and pSG1107 
(Scarab Genomics LLC, Madison, Wisc., USA). Cells were gener-
ally grown aerobically either in liquid (shaking) or on solid Luria-
Bertani (LB) medium (1% bactotryptone, 0.5% yeast extract, and 
0.5% sodium chloride) [Miller, 1992] at 37  °  C. Media were supple-
mented when appropriate with either ampicillin (100   g/ml; Sig-
ma Aldrich, St. Louis, Mo., USA) or chloramphenicol (12.5   g/ml; 
Sigma Aldrich).
 DNA Sequencing 
 DNA sequencing of the modified transporter construct in-
serted in pSG1502 and pAZ1 expression plasmids was performed 
by automated DNA sequencing on an ABI 3100 instrument based 
on dideoxy chain termination method [Sanger et al., 1977], using 
M13 primers for plasmid pAZ1 and pSG1502.
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 Transformation of  E. coli Strains 
 E. coli strains were made competent and transformed using 
standard techniques [Dower et al., 1988]. Briefly, either a 100-ng 
aliquot of the ligation mixture or a 20-ng aliquot of the corre-
sponding plasmid was added to 40   l of electrocompetent  E. coli 
cells, and the mixed solution was transferred into an ice-cold 0.2-
cm disposable cuvette (Bio-Rad Laboratories, Hercules, Calif., 
USA). Electroporation was conducted using a Gene Pulser Xcell 
electroporation system (Bio-Rad Laboratories) at 2.5 kV, 25   F, 
and 400   and was immediately followed by the addition of 1 ml 
of SOC medium (SOB medium containing 20 m M glucose, 10 m M 
MgSO 4 , and 10 m M MgCl 2 ). The culture was then incubated for 
1 h at 37  °  C. 10- and 100-  l aliquots as well as the rest volume were 
spread onto LB agar containing either chloramphenicol or ampi-
cillin and incubated for 16–18 h at 37  °  C to select for the antibiot-
ic-resistant recombinants. Successful transformants were con-
firmed by mini-prep growth with plasmid extraction followed by 
restriction digestion and gel electrophoresis.
 Construction of the Secretion Vectors 
 Molecular methods were performed as described by Sam-
brook et al. [1989]. To construct plasmid pSG1502, a 561-bp DNA 
fragment including the first 66 nucleotides of the  E. coli  ompF 
gene (NC_000913.2) encoding the signal peptide sequence fused 
in frame to an  E. coli codon-optimized gene of the mature hIL-
10 (NM_000572) was de novo synthesized by Bio Basic Inc. 
(Markham, Ont., Canada) and subsequently cloned into NdeI/
HindIII digested pSG1107 vector resulting in plasmid pSG1502. 
For increased protein expression, a 683-bp fragment (including 
the hIL-10 gene and the T7 promoter region) was amplified from 
pSG1502 using Phusion DNA polymerase (New England Biolabs) 
and the primers SG1502T7for (GCG AAT TCC ACG ACC CTA 
GAG TCG AG) and SG1502h-IL10rev (GCG AAT TCC AAG 
GGG TTA TGC TAG TTA TC). The PCR fragment was  Eco RI 
digested and subsequently ligated into  Eco RI digested pUC19 re-
sulting in the expression plasmid pAZ1.
 hIL-10 Sample Preparation 
 E. coli BL21 (DE3) and MDS42:T7 cells transformed with plas-
mid pAZ1 were grown overnight at 37   °   C in 50 ml of LB broth 
containing 100   g/ml of ampicillin. From overnight cultures, the 
culture supernatant was removed and sterile filtered (0.20   m; 
Sarstedt, Nümbrecht, Germany). The periplasmic fraction was 
prepared according to the method of Neu and Heppel [1965]. 
Briefly, the cell pellet was resuspended in ice-cold protoplast buf-
fer containing 30 m M Tris-HCl, 40% sucrose, and 2 m M EDTA at 
1/10 of the culture volume. After 15 min of incubation on ice, the 
cells were centrifuged at 5,000  g for 60 min at 4  °  C. The superna-
tant fluid was discarded, and the pellet was resuspended in a vol-
ume of cold ddH 2 O equal to that of the original volume of the 
suspension. After 15 min of incubation on ice and centrifugation, 
the supernatant fluid equivalent to the periplasmic fraction was 
collected.
 Quantification of hIL-10 Expression 
 Recombinant hIL-10 levels were quantified via sandwich ELI-
SA (R&D Systems). The assay was carried out according to the 
manufacturer’s instructions. All samples were measured in dupli-
cate at 450–540 nm, and cytokine levels were determined by lin-
ear regression analysis using a standard curve generated with the 
supplied calibration material. As negative controls, supernatant 
and periplasmic fraction from pUC19-transformed  E. coli BL21 
(DE3) and MDS42:T7 cells were used. The hIL-10 concentrations 
were the result of three independent experiments and presented 
as means  8 SD.
 SDS-PAGE and BN-PAGE hIL-10 Immunoblot Analysis 
 Periplasmic fractions of pAZ1-transformed  E. coli BL21 (DE3) 
cells were separated by SDS-PAGE on a 10% (w/v) NuPAGE Novex 
Bis-Tris gel (Invitrogen) prior to blotting onto nitrocellulose 
which was blocked for 1.5 h with PBS supplemented with 10% 
(w/v) FCS and 0.1% Tween 20. Membranes were incubated over-
night at 4  °  C with a rabbit anti-hIL-10 antibody (PeproTech, Rocky 
Hills, N.J., USA) diluted at 1: 5,000, followed by a second 1-hour 
incubation step at room temperature with a horseradish peroxi-
dase-conjugated goat anti-rabbit immunoglobulin G (Jackson 
ImmunoResearch, West Grove, Pa., USA) diluted at 1: 30,000. 
Chemoluminescence was detected by incubation with tetrameth-
ylbenzidine-H 2 O 2 as substrate and subsequent analysis with a 
LAS 3000 (Fujifilm Europe, Düsseldorf, Germany) bioimager. 
Commercial hIL-10 (R&D Systems) was used as standard.
 Blue-native electrophoresis was performed using pre-cast, 1.0 
mm 7  ! 8 cm, polyacrylamide 4–16% gradient SERVA N gels 
(SERVA Electrophoresis) according to the manufacturer’s in-
structions. Anode buffer was 50 m M Bis-Tris-HCl (pH 7.0) and 
cathode buffer was 15 m M Bis-Tris, 50 m M Tricine and 0.002% 
(w/v) SERVA Blue G as additive (pH 7.0) (SERVA Electrophoresis). 
Protein samples (ca. 0.1–0.3   g hIL-10) were mixed with 2  ! blue 
native sample buffer (SERVA Electrophoresis) at a volume ratio of 
3: 1 and loaded onto the gel. BN-PAGE was conducted at 50 V for 
10 min and thereafter at 200 V until the blue dye reached the bot-
tom of the gel. Protein blotting was carried out using PVDF mem-
branes and Towbin transfer buffer (0.025  M Tris, 0.192  M glycine) 
containing 20% (v/v) methanol. Protein detection was performed 
as described for SDS-PAGE immunoblot analysis.
 SDS-PAGE and BN-PAGE immunoblot data were the result of 
at least two independent experiments.
 In vitro Assays for Characterization of hIL-10 Biological 
Activity 
 (a) TNF-  Cell Assay. Prior to the experiment, J774.1 cells were 
seeded at a density of 1  ! 10 5 /ml in 24-well tissue culture plates 
and were then incubated for 2 h at 37   °   C. Recombinant hIL-10 
from the periplasmic fraction of pAZ1-transformed  E. coli BL21 
(DE3) cells was either preincubated alone at 37  °  C, in the presence 
of neutralizing anti-IL-10 monoclonal antibody (R&D Systems) 
or denatured at 95   °  C for 30 min, filled up to equal volumes with 
LPS containing periplasmic fraction of pUC19-transformed  E. 
coli BL21 (DE3) cells, and then added to J774.1 cells at a concen-
tration of 50 ng/ml. After 4 h of incubation at 37   °   C, the amount 
of TNF-  released in the medium was measured in duplicate by 
ELISA (R&D Systems) according to the manufacturer’s instruc-
tions. Periplasmic fraction of pUC19-transformed  E. coli BL21 
(DE3) was used as TNF-  induction control. Commercial hIL-10 
(R&D Systems) served as positive control. Presented values were 
the result of five independent experiments.
 (b) STAT3 Cell Assay. J774.1 cells were incubated for 30 min at 
5  ! 10 6 per well with recombinant hIL-10 from the periplasmic 
fraction of pAZ1-transformed  E. coli BL21 (DE3) cells, then har-
vested and treated with cell lysis buffer (RIPA buffer; Sigma Al-
 Pöhlmann  /Brandt  /Mottok  /Zschüttig  /
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J Mol Microbiol Biotechnol 2012;22:1–9 8
drich) containing inhibitors of proteases (Complete Mini; Roche 
Applied Science, Mannheim, Germany) and phosphatases (Phos-
phostop; Roche Applied Science) for 1 h at 4  °  C. Cell lysates were 
clarified by centrifugation, and the supernatants were then ana-
lyzed by SDS-PAGE on a 10% (w/v) NuPAGE Novex Bis-Tris gel 
(Invitrogen) and subsequent immunoblotting with polyclonal an-
tibodies directed against either phospho-STAT3 (Y705) (Cell Sig-
naling Technology, Danvers, Mass., USA) or total STAT3 (C-20) 
(Santa Cruz Biotechnology, Santa Cruz, Calif., USA), both diluted 
at 1: 1,000. Horseradish peroxidase-conjugated goat anti-rabbit 
immunoglobulin G (Jackson ImmunoResearch) diluted at 1: 
 25,000 was utilized for detection. The periplasmic fraction of 
pUC19-transformed  E. coli BL21 (DE3) and commercial hIL-10 
(R&D Systems) were used as controls. STAT3 immunoblot data 
were the result of at least two independent experiments.
 Statistical Analysis 
 All data presented as means  8 SD. Student’s t test was used to 
determine the statistical significance. p  ! 0.05 was considered sta-
tistically significant.
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